Pharma Pulse: CVS Caremark Faces $290M Penalty, Small Practices Miss HIPAA Standards, and Pharmacists Underreport Adverse Drug Reactions

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering a major legal ruling against CVS Caremark, new concerns about HIPAA compliance among small practices, and the role of pharmacists in adverse drug reaction reporting.

• A federal court has ordered CVS Caremark to pay $290 million in a False Claims Act case tied to Medicare Part D. The whistleblower lawsuit alleged that the company improperly reported drug pricing data, inflating costs to federal programs. The ruling highlights ongoing scrutiny of pharmacy benefit managers and their role in drug pricing transparency, an issue that continues to attract bipartisan attention from lawmakers and regulators.
• In other news, a new report finds that while most small medical practices believe they are compliant with HIPAA requirements, the majority actually fall short. The analysis points to gaps in risk assessments, employee training, and safeguards for electronic health records. These shortcomings leave practices vulnerable not only to regulatory penalties but also to data breaches that could compromise patient privacy. Experts stress the need for better education, resources, and auditing to ensure compliance in smaller healthcare settings.
• Lastly, a recent study has found that many pharmacists lack both knowledge and motivation when it comes to reporting adverse drug reactions. Although pharmacists are often the first to identify potential safety issues, barriers like limited training, lack of time, and unclear reporting systems contribute to underreporting. Strengthening education and streamlining reporting tools could help improve pharmacovigilance and patient safety.

From drug pricing accountability to compliance gaps and safety reporting, these stories reflect the challenges and opportunities at the intersection of pharma, healthcare, and regulation.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.